[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)]
- PMID: 7206588
- DOI: 10.1007/BF01477050
[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)]
Abstract
A sensitive reproducible, nondestructive method for the determination of adriamycin and its metabolites in plasma, leukocytes and tissues has been developed. Apolar substances as adriamycinone (adm-one) were extracted at pH 2 with chloroform, polar ones as adriamycin (adm) and adriamycinol (adm-ol) at pH 8.8 with chloroform: methanol, separated by thin-layer-chromatography and quantitated by fluorescence spectrophotometry. The plasma levels of adm-ol and adm-one were lower in all patients compared to those of adm. Further metabolites were found in the bile. Toxic effects were found in patients with prolonged half-lives in the elimination phase. A delayed elimination was observed in a patient with an elevation of the bilirubin level, but also in patients without overt liver disease. The pharmacokinetics of adm showed considerable inter- and intraindividual fluctuations.
Similar articles
-
Quantitative determination of adriamycin in rat hepatocytes using a volatile extraction buffer, HPLC and fluorescence detection.Biomed Chromatogr. 1987;2(3):91-4. doi: 10.1002/bmc.1130020302. Biomed Chromatogr. 1987. PMID: 3507221
-
Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.Eur J Cancer Clin Oncol. 1986 Aug;22(8):991-1001. doi: 10.1016/0277-5379(86)90067-2. Eur J Cancer Clin Oncol. 1986. PMID: 3770056
-
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.Cancer Res. 1977 May;37(5):1416-20. Cancer Res. 1977. PMID: 856462
-
Bilary disposition of adriamycin.Clin Pharmacol Ther. 1977 Aug;22(2):234-41. doi: 10.1002/cpt1977222234. Clin Pharmacol Ther. 1977. PMID: 884924
-
Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.Cancer Chemother Pharmacol. 1985;15(2):132-40. doi: 10.1007/BF00257523. Cancer Chemother Pharmacol. 1985. PMID: 4017162
Cited by
-
Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.Med Oncol Tumor Pharmacother. 1985;2(1):47-54. doi: 10.1007/BF02934780. Med Oncol Tumor Pharmacother. 1985. PMID: 4058077
-
Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.J Cancer Res Clin Oncol. 1987;113(6):593-8. doi: 10.1007/BF00390872. J Cancer Res Clin Oncol. 1987. PMID: 2824523 Free PMC article.
-
Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions.Br J Cancer. 1984 Sep;50(3):351-5. doi: 10.1038/bjc.1984.182. Br J Cancer. 1984. PMID: 6466545 Free PMC article.
-
Time dependency of adriamycin and adriamycinol kinetics.Cancer Chemother Pharmacol. 1983;10(2):120-4. doi: 10.1007/BF00446223. Cancer Chemother Pharmacol. 1983. PMID: 6831625
-
Acute negative inotropic effect of adriamycin (doxorubicin).Naunyn Schmiedebergs Arch Pharmacol. 1981 Nov;317(3):252-6. doi: 10.1007/BF00503826. Naunyn Schmiedebergs Arch Pharmacol. 1981. PMID: 7322214
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources